Protocol Ledger

NCT06712654 · Phase II · RECRUITING

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

Interventional Phase II clinical trial protocol NCT06712654 sponsored by R1 Therapeutics in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-01 Enrollment: 168 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06712654
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)168 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06712654
Protocol FieldVerified Registry Value
NCT IdentifierNCT06712654
Consolidated Lead SponsorR1 Therapeutics
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment168 participants (ESTIMATED)
Registered Start Date2026-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06712654
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI